Skip to main content
. Author manuscript; available in PMC: 2016 Jan 31.
Published in final edited form as: Nat Med. 2015 Jul 13;21(8):887–894. doi: 10.1038/nm.3882

Figure 3. Sirt1 is necessary and sufficient for the metabolic effects of Nnmt.

Figure 3

(a) Immunobloting of acetylated, total FoxO1 and their ratio in control and Nnmt knockdown primary hepatocytes (triplicate determination). (b) Immunobloting of acetylated, total FoxO1 and their ratio in control and Nnmt overexpressing primary hepatocytes (triplicate determination). (c) Immunoblotting of acetylated and total FoxO1 and their ratio in the livers of control and Nnmt knockdown mice (shcontrol n = 6, shNnmt n = 7). (d) Expression of G6pc and Pck1 in control and Nnmt overexpressing primary hepatocytes treated with the Sirt1 inhibitor sirtinol (representative of 2 independent experiments performed in triplicates). (e) Expression of G6pc and Pck1 in control and Nnmt overexpressing primary hepatocytes treated with the Sirt1 inhibitor Ex-527 (performed in triplicates). (f) Effect of EX-527 on glucose production in control and Nnmt overexpressing primary hepatocytes (triplicate determination). (g) Expression of G6pc and Pck1 in control and Nnmt knockdown primary hepatocytes with Sirt1 overexpression (AdSirt1) (triplicate determination). Data are presented as mean ± s.e.m. Statistical significance was tested by unpaired Student’s t-test, *P < 0.05).